Home > Research > Publications & Outputs > Bayesian sample size determination using commen...

Links

Text available via DOI:

View graph of relations

Bayesian sample size determination using commensurate priors to leverage pre‐experimental data

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Bayesian sample size determination using commensurate priors to leverage pre‐experimental data. / Zheng, Haiyan; Jaki, Thomas; Wason, James M.S.
In: Biometrics, Vol. 79, No. 2, 30.06.2023, p. 669-683.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Zheng H, Jaki T, Wason JMS. Bayesian sample size determination using commensurate priors to leverage pre‐experimental data. Biometrics. 2023 Jun 30;79(2):669-683. Epub 2022 Mar 28. doi: 10.1111/biom.13649

Author

Bibtex

@article{cb35eedf1c374363ba9068236f5417fc,
title = "Bayesian sample size determination using commensurate priors to leverage pre‐experimental data",
abstract = "This paper develops Bayesian sample size formulae for experiments comparing two groups, where relevant preexperimental information from multiple sources can be incorporated in a robust prior to support both the design and analysis. We use commensurate predictive priors for borrowing of information and further place Gamma mixture priors on the precisions to account for preliminary belief about the pairwise (in)commensurability between parameters that underpin the historical and new experiments. Averaged over the probability space of the new experimental data, appropriate sample sizes are found according to criteria that control certain aspects of the posterior distribution, such as the coverage probability or length of a defined density region. Our Bayesian methodology can be applied to circumstances that compare two normal means, proportions, or event times. When nuisance parameters (such as variance) in the new experiment are unknown, a prior distribution can further be specified based on preexperimental data. Exact solutions are available based on most of the criteria considered for Bayesian sample size determination, while a search procedure is described in cases for which there are no closed-form expressions. We illustrate the application of our sample size formulae in the design of clinical trials, where pretrial information is available to be leveraged. Hypothetical data examples, motivated by a rare-disease trial with an elicited expert prior opinion, and a comprehensive performance evaluation of the proposed methodology are presented.",
keywords = "bayesian experimental designs, historical data, rare-disease trials, robustness, sample size",
author = "Haiyan Zheng and Thomas Jaki and Wason, {James M.S.}",
year = "2023",
month = jun,
day = "30",
doi = "10.1111/biom.13649",
language = "English",
volume = "79",
pages = "669--683",
journal = "Biometrics",
issn = "0006-341X",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Bayesian sample size determination using commensurate priors to leverage pre‐experimental data

AU - Zheng, Haiyan

AU - Jaki, Thomas

AU - Wason, James M.S.

PY - 2023/6/30

Y1 - 2023/6/30

N2 - This paper develops Bayesian sample size formulae for experiments comparing two groups, where relevant preexperimental information from multiple sources can be incorporated in a robust prior to support both the design and analysis. We use commensurate predictive priors for borrowing of information and further place Gamma mixture priors on the precisions to account for preliminary belief about the pairwise (in)commensurability between parameters that underpin the historical and new experiments. Averaged over the probability space of the new experimental data, appropriate sample sizes are found according to criteria that control certain aspects of the posterior distribution, such as the coverage probability or length of a defined density region. Our Bayesian methodology can be applied to circumstances that compare two normal means, proportions, or event times. When nuisance parameters (such as variance) in the new experiment are unknown, a prior distribution can further be specified based on preexperimental data. Exact solutions are available based on most of the criteria considered for Bayesian sample size determination, while a search procedure is described in cases for which there are no closed-form expressions. We illustrate the application of our sample size formulae in the design of clinical trials, where pretrial information is available to be leveraged. Hypothetical data examples, motivated by a rare-disease trial with an elicited expert prior opinion, and a comprehensive performance evaluation of the proposed methodology are presented.

AB - This paper develops Bayesian sample size formulae for experiments comparing two groups, where relevant preexperimental information from multiple sources can be incorporated in a robust prior to support both the design and analysis. We use commensurate predictive priors for borrowing of information and further place Gamma mixture priors on the precisions to account for preliminary belief about the pairwise (in)commensurability between parameters that underpin the historical and new experiments. Averaged over the probability space of the new experimental data, appropriate sample sizes are found according to criteria that control certain aspects of the posterior distribution, such as the coverage probability or length of a defined density region. Our Bayesian methodology can be applied to circumstances that compare two normal means, proportions, or event times. When nuisance parameters (such as variance) in the new experiment are unknown, a prior distribution can further be specified based on preexperimental data. Exact solutions are available based on most of the criteria considered for Bayesian sample size determination, while a search procedure is described in cases for which there are no closed-form expressions. We illustrate the application of our sample size formulae in the design of clinical trials, where pretrial information is available to be leveraged. Hypothetical data examples, motivated by a rare-disease trial with an elicited expert prior opinion, and a comprehensive performance evaluation of the proposed methodology are presented.

KW - bayesian experimental designs

KW - historical data

KW - rare-disease trials

KW - robustness

KW - sample size

U2 - 10.1111/biom.13649

DO - 10.1111/biom.13649

M3 - Journal article

VL - 79

SP - 669

EP - 683

JO - Biometrics

JF - Biometrics

SN - 0006-341X

IS - 2

ER -